{
  "id": 10601489,
  "title": "US waives 100% tariff on select Indian speciality drugs",
  "url": "https://urgent.news/2026/09/29/us-waives-100-tariff-on-select-indian-speciality-drugs",
  "topic": "world",
  "section": "World",
  "published": "2026-09-29T03:41:30.000Z",
  "source": {
    "name": "The Indian Express",
    "slug": "the-indian-express",
    "url": "https://indianexpress.com/article/world/us-pharma-tariffs-indian-speciality-drugs-donald-trump-10898369/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The US Commerce Department has announced a waiver of 100% tariff on select Indian speciality drugs, as per a notice issued by the department. This move comes after President Donald Trump announced a 100% tariff on specified licensed pharmaceutical products, aiming to encourage domestic production. The waiver applies to specific categories of speciality medicines, including rare diseases, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapies, antibody-drug conjugates (ADCs), and certain medicines used to deal with chemical, biological, radiological, and nuclear threats. Animal medicines are also covered under this waiver. The US had imposed the tariff under Section 232 of the Trade Expansion Act, which came into effect on July 31. However, the tariff does not currently apply to generic pharmaceutical products and their associated ingredients, which are crucial for India as a large part of its drug exports to the US are generic medicines. India is among 20 jurisdictions eligible for the waiver, joining countries such as Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland, Liechtenstein, Taiwan, Thailand, the United Kingdom, and Vietnam.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}